MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model
Costello syndrome (CS) is a congenital disorder caused by heterozygous activating germline HRAS mutations in the canonical Ras/mitogen-activated protein kinase (Ras/MAPK) pathway. CS is one of the RASopathies, a large group of syndromes caused by mutations within various components of the Ras/MAPK p...
| Published in: | Disease Models & Mechanisms |
|---|---|
| Main Authors: | William E. Tidyman, Alice F. Goodwin, Yoshiko Maeda, Ophir D. Klein, Katherine A. Rauen |
| Format: | Article |
| Language: | English |
| Published: |
The Company of Biologists
2022-02-01
|
| Subjects: | |
| Online Access: | http://dmm.biologists.org/content/15/2/dmm049166 |
Similar Items
Increased osteoclastogenesis contributes to bone loss in the Costello syndrome Hras G12V mouse model
by: Sayantan Nandi, et al.
Published: (2022-10-01)
by: Sayantan Nandi, et al.
Published: (2022-10-01)
RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development
by: Katherine A. Rauen, et al.
Published: (2024-06-01)
by: Katherine A. Rauen, et al.
Published: (2024-06-01)
Hepatic Tumor as Antenatal Presentation of Costello Syndrome
by: Chusana Petpichetchian, et al.
Published: (2021-03-01)
by: Chusana Petpichetchian, et al.
Published: (2021-03-01)
Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes
by: Anna Papadopoulou, et al.
Published: (2023-10-01)
by: Anna Papadopoulou, et al.
Published: (2023-10-01)
Rapid Weight Loss and Severe Failure to Thrive Mimicking Lipodystrophy Syndrome in a 1-Year-Old Taiwanese Girl with Costello Syndrome
by: Yu-Min Syu, et al.
Published: (2022-06-01)
by: Yu-Min Syu, et al.
Published: (2022-06-01)
Cardiofaciocutaneous Syndrome: Case Report of a Rare Disorder
by: Soutrik Seth, et al.
Published: (2016-11-01)
by: Soutrik Seth, et al.
Published: (2016-11-01)
The RASopathies: from pathogenetics to therapeutics
by: Katie E. Hebron, et al.
Published: (2022-02-01)
by: Katie E. Hebron, et al.
Published: (2022-02-01)
Caspase 3‐specific cleavage of MEK1 suppresses ERK signaling and sensitizes cells to stress‐induced apoptosis
by: Hisashi Moriizumi, et al.
Published: (2023-04-01)
by: Hisashi Moriizumi, et al.
Published: (2023-04-01)
Dysplastic Mitral Valve in Costello Syndrome
by: Tamara Naneishvili, MBBS, et al.
Published: (2024-07-01)
by: Tamara Naneishvili, MBBS, et al.
Published: (2024-07-01)
Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice
by: Rocío Fuentes-Mateos, et al.
Published: (2024-06-01)
by: Rocío Fuentes-Mateos, et al.
Published: (2024-06-01)
Costello Syndrome: The Challenge of Hypoglycemia and Failure to Thrive
by: C. Leoni, et al.
Published: (2018-01-01)
by: C. Leoni, et al.
Published: (2018-01-01)
Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary
by: Cevriye Cansız Ersöz
Published: (2020-08-01)
by: Cevriye Cansız Ersöz
Published: (2020-08-01)
Treatment of Dystonia Using Trihexyphenidyl in Costello Syndrome
by: Domenico M. Romeo, et al.
Published: (2020-07-01)
by: Domenico M. Romeo, et al.
Published: (2020-07-01)
Updated ACMG/AMP specifications for variant interpretation and gene curations from the ClinGen RASopathy expert panels
by: Emma H. Wilcox, et al.
Published: (2025-01-01)
by: Emma H. Wilcox, et al.
Published: (2025-01-01)
Costello Syndrome. A case report
by: Yadelis Maldonado Martínez, et al.
Published: (2014-06-01)
by: Yadelis Maldonado Martínez, et al.
Published: (2014-06-01)
Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib
by: Yannik Andrasch, et al.
Published: (2025-02-01)
by: Yannik Andrasch, et al.
Published: (2025-02-01)
Fatal leukodystrophy in Costello syndrome: a case report
by: Virgilio E. Failoc-Rojas, et al.
Published: (2023-07-01)
by: Virgilio E. Failoc-Rojas, et al.
Published: (2023-07-01)
Syndrome in question
by: Isy Lima Peixoto, et al.
Published: (2014-12-01)
by: Isy Lima Peixoto, et al.
Published: (2014-12-01)
RASopathies and cardiac manifestations
by: Nazia Hilal, et al.
Published: (2023-07-01)
by: Nazia Hilal, et al.
Published: (2023-07-01)
J.M. Coetzee and Elizabeth Costello: Landscapes and Animals
by: Lucilla Spini
Published: (2020-08-01)
by: Lucilla Spini
Published: (2020-08-01)
Síndrome Costello. Reporte de un caso
by: Elayne E. Santana Hernández, et al.
Published: (2017-01-01)
by: Elayne E. Santana Hernández, et al.
Published: (2017-01-01)
Síndrome Costello. Reporte de un caso
by: Elayne E. Santana Hernández, et al.
Published: (2017-01-01)
by: Elayne E. Santana Hernández, et al.
Published: (2017-01-01)
MEK inhibitors for the treatment of extracranial arteriovenous malformations
by: Zi’an Xu, et al.
Published: (2023-09-01)
by: Zi’an Xu, et al.
Published: (2023-09-01)
Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient
by: Irene Baquedano Lobera, et al.
Published: (2019-04-01)
by: Irene Baquedano Lobera, et al.
Published: (2019-04-01)
Síndrome de Noonan: actualización genética, clínica y de opciones terapéuticas
by: Atilano Carcavilla, et al.
Published: (2020-07-01)
by: Atilano Carcavilla, et al.
Published: (2020-07-01)
A Patient with Noonan Syndrome with a KRAS Mutation Who Presented Severe Nerve Root Hypertrophy
by: Yoshihito Ando, et al.
Published: (2021-02-01)
by: Yoshihito Ando, et al.
Published: (2021-02-01)
Editorial: Endocrine aspects of Noonan syndrome and related syndromes
by: Giorgio Radetti, et al.
Published: (2023-01-01)
by: Giorgio Radetti, et al.
Published: (2023-01-01)
Character Adrift (on the Sea of Language): Robinson Crusoe, Foe, Elizabeth Costello, and the Shipwreck of Realism
by: James CORBY
Published: (2024-06-01)
by: James CORBY
Published: (2024-06-01)
Editorial: Identifying the isoform-specific roles of RAS paralogs in health and disease
by: Saeideh Nakhaei-Rad, et al.
Published: (2023-04-01)
by: Saeideh Nakhaei-Rad, et al.
Published: (2023-04-01)
Shattering Dietary Taboos in Post-Pandemic Era: Human-Animal Interaction in J. M. Coetzee’s Elizabeth Costello
by: Baturay Erdal
Published: (2022-06-01)
by: Baturay Erdal
Published: (2022-06-01)
Trametinib restores the central conducting lymphatic flow in a premature infant with Noonan syndrome
by: Erika K. S. M. Leenders, et al.
Published: (2024-07-01)
by: Erika K. S. M. Leenders, et al.
Published: (2024-07-01)
Non-Mammalian Models for Understanding Neurological Defects in RASopathies
by: Mario Rodríguez-Martín, et al.
Published: (2024-04-01)
by: Mario Rodríguez-Martín, et al.
Published: (2024-04-01)
Clinical and Cytometric Study of Immune Involvement in a Heterogeneous Cohort of Subjects With RASopathies and mTORopathies
by: Erica Valencic, et al.
Published: (2021-08-01)
by: Erica Valencic, et al.
Published: (2021-08-01)
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
by: Anais Del Curatolo, et al.
Published: (2018-07-01)
by: Anais Del Curatolo, et al.
Published: (2018-07-01)
Assessment of the FRET-based Teen sensor to monitor ERK activation changes preceding morphological defects in a RASopathy zebrafish model and phenotypic rescue by MEK inhibitor
by: Giulia Fasano, et al.
Published: (2024-04-01)
by: Giulia Fasano, et al.
Published: (2024-04-01)
MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)
by: Sarkisian S, et al.
Published: (2018-08-01)
The Surgical Management of Severe Scoliosis in Immature Patient with a Very Rare Disease Costello Syndrome—Clinical Example and Brief Literature Review
by: Pawel Grabala, et al.
Published: (2024-06-01)
by: Pawel Grabala, et al.
Published: (2024-06-01)
<i>Is This the Gate?</i>: J. M. Coetzee’s <i>Elizabeth Costello</i> and Its Operatic Adaptation
by: Xingyu Lin
Published: (2025-03-01)
by: Xingyu Lin
Published: (2025-03-01)
RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation
by: Rohan Chippalkatti, et al.
Published: (2024-06-01)
by: Rohan Chippalkatti, et al.
Published: (2024-06-01)
Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome
by: Isabel De Brouchoven, et al.
Published: (2025-02-01)
by: Isabel De Brouchoven, et al.
Published: (2025-02-01)
Similar Items
-
Increased osteoclastogenesis contributes to bone loss in the Costello syndrome Hras G12V mouse model
by: Sayantan Nandi, et al.
Published: (2022-10-01) -
RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development
by: Katherine A. Rauen, et al.
Published: (2024-06-01) -
Hepatic Tumor as Antenatal Presentation of Costello Syndrome
by: Chusana Petpichetchian, et al.
Published: (2021-03-01) -
Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes
by: Anna Papadopoulou, et al.
Published: (2023-10-01) -
Rapid Weight Loss and Severe Failure to Thrive Mimicking Lipodystrophy Syndrome in a 1-Year-Old Taiwanese Girl with Costello Syndrome
by: Yu-Min Syu, et al.
Published: (2022-06-01)
